http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-088848-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate | 2012-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-088848-A2 |
| titleOfInvention | PHARMACEUTICAL COMPOSITION THAT INCLUDES A SUBSTITUTED BICYCLE AZAHETEROCICLYL COMPOUND, USE OF SUCH COMPOUND TO MANUFACTURE IT AND PHARMACEUTICAL EQUIPMENT OR PACKAGE THAT UNDERSTANDS IT |
| abstract | This refers to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as NS3 hepatitis C protease inhibitors; their intermediates, their preparation, including stereoselective procedures with respect to intermediates. It also refers to pharmaceutical compositions and methods for using the compounds to inhibit HCV protease or to treat a patient suffering from HCV infection or a physiological condition related to the infection. Pharmaceutical combinations are also provided which comprise, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and / or one or more compounds with anti-HCV activity and a pharmaceutically acceptable carrier, and methods for Treat or prevent an HCV infection in a patient by using the compositions. It also refers to a pharmaceutical equipment or package to treat or prevent HCV infection in a patient. Claim 1: A pharmaceutical composition characterized in that it comprises a pharmaceutically acceptable amount of the substituted bicyclic azaheterocyclyl compound of formula (1) or a pharmaceutically acceptable salt of said compound, and a pharmaceutically acceptable carrier. Claim 2: A pharmaceutical composition according to claim 1, further characterized in that it comprises an interferon that possesses hepatitis C (HCV) antivirus activity. Claim 5: The pharmaceutical composition according to claim 3, characterized in that said compound of the formula (1), said interferon and said compound possessing hepatitis C antivirus activity, each is present in an amount selected from the group consisting of a pharmaceutically effective amount, a pharmaceutically effective subclinical amount and a combination thereof. Claim 6: The pharmaceutical composition according to claim 5, characterized in that said interferon is selected from the group consisting of interferon at 2B, interferon to pegylated, interferon consensus, interferon at 2A, lymphoblastoid interferon and interferon t; and wherein said compound with hepatitis C antiviral activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that improves the development of type 1 helper T cell response, double stranded RNA, complex double stranded RNA with tobramycin, imiquimod, ribavirin, an inosine 5-monophosphate dehydrogenase inhibitor, amantadine and rimantadine. |
| priorityDate | 2012-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 206.